letetresgene autoleucel
Cell therapy
Evidence outlook · no controlled comparison
NCT05993299 · Neoplasms
The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.
NCT05993299: The study was open-label, nonrandomized, and had no comparator arm, with only 5 participants included in the reported response analysis. Although the primary RECIST 1.1 tumor-response endpoint showed an 80% response rate, the uncontrolled design cannot establish how much benefit was caused by letetresgene autoleucel.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05993299 NCT05993299 · Neoplasms Study of the molecule, not a specific product The study was open-label, nonrandomized, and had no comparator arm, with only 5 participants included in the reported response analysis. Although the primary RECIST 1.1 tumor-response endpoint showed an 80% response rate, the uncontrolled design cannot establish how much benefit was caused by letetresgene autoleucel. Registry: NCT05993299 | 2 | Overall Response Rate (ORR) (Up to approximately 36 months) 2022-10-12 | Overall Response Rate (ORR) (Up to approximately 36 months): Letetresgene Autoleucel (Lete-cel) 80 percentage of participants (95% CI 28.4 to 99.5) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.